吉非替尼靶向治疗非小细胞肺癌前后血清肿瘤标志物的改变及临床意义

Changes and clinical significance of serum tumor markers in patients with non-small cell lung cancer before and after gefitinib targeted therapy

目的探讨吉非替尼靶向治疗非小细胞肺癌前后血清肿瘤标志物的改变及临床意义。方法选取本院于2015年6月至2017年5月收治的非小细胞肺癌患者80例,采用随机数字表法将患者分为对照组和观察组,每组40例,对照组患者采用多西他赛常规化疗,观察组患者实施吉非替尼靶向治疗,观察并比较两组患者的临床治疗效果及治疗前后血清肿瘤标志物抗原125(CA125)、癌胚抗原(CEA)、神经元特异烯醇化酶(NSE)的变化以及不良反应。结果观察组的有效率高于对照组,且观察组的病情控制率高于对照组,差异具有统计学意义(P <0. 05);治疗前,对照组和观察组的血清肿瘤标志物CA125、CEA、NSE水平比较差异无统计学意义(P> 0.05),治疗1个月后,两组患者的血清肿瘤标志物CA125、CEA、NSE水平均降低,且观察组的血清肿瘤标志物CA125、CEA、NSE水平均低于对照组,差异具有统计学意义(P <0. 05);观察组的不良反应总发生率低于对照组,差异具有统计学意义(P<0.05)。结论吉非替尼靶向治疗非小细胞肺癌的治疗效果显著,降低血清肿瘤标志物CA125、CEA、NSE水平,减少术后不良反应,值得临床推广应用。

Objective To investigate the changes and clinical significance of serum tumor markers in patients with non-small cell lung cancer before and after gefitinib targeted therapy. Methods 80 cases of non-small cell lung cancer patients in our hospital from June 2015 to May 2017 were divided into control group and observation group randomly, 40 cases in each group. The control group were treated with docetaxel conventional chemotherapy, and the observation group were treated with gefitinib targeted therapy. The clinical treatment effect, changes of serum tumor markers cancer antigen125 （CA125）, carcinoembryonic antigen （ CEA）, neuron specific enolase （NSE） and adverse reactions were observed and compared between the two groups before and after treatment. Results The effective rate and disease control rate of the observation group were higher than that in the control group, with statistically significant difference （P 〈 0. 05 ）. The levels of serum tumor markers CA125, CEA and NSE in the control group and the observation group before treatment were not significantly different （P 〉 0.05 ）. After 1 months of treatment, the levels of serum tumor markers CA125, CEA and NSE in the two groups were all decreased, and the level of serum tumor markers, CA125, CEA and NSE in the observation group were lower than those in the control group, with statistically significant difference. The incidence of adverse reactions in the observation group was lower than that in the control group （P 〈 0. 05）, with statistically significant difference. Conclusions Gefitinib is effective in the treatment of non-small cell lung cancer. It reduces the level of serum tumor markers CA125, CEA, NSE, and reduces postoperative adverse reactions. It is worthy of clinical application.